Wilex announces positive results from Phase I study of MEK inhibitor WX-554.

(ADPnews) - Jun 17, 2010 - German biopharmaceutical company Wilex AG (ETR:WL6) announced on Thursday it had completed the Phase I study of the Mitogen activated protein kinase (MEK) inhibitor WX 554 and had drawn positive results.

The study demonstrated for the first time WX-554's activity in humans, the company said.

The Phase I trial was aimed at testing the safety of the substance, its tolerability in the patients and at determining the optimal dosage for the inhibition of the MEK system by WX-554. The trial also tested the pharmacokinetic and pharmacodynamic properties of the MEK inhibitor.

Wilex said the substance was safe and well tolerated in …